Swiss National Bank continued to hold its stake in shares of FibroGen Inc. (NASDAQ:FGEN) during the second quarter, Holdings Channel reports. The firm owned 80,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Swiss National Bank owned approximately 0.13% of FibroGen worth $1,313,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Acadian Asset Management LLC bought a new stake in shares of FibroGen during the second quarter valued at about $106,000. Quantbot Technologies LP bought a new stake in shares of FibroGen during the second quarter valued at about $164,000. Fox Run Management L.L.C. bought a new stake in shares of FibroGen during the second quarter valued at about $176,000. RMB Capital Management LLC bought a new stake in shares of FibroGen during the first quarter valued at about $213,000. Finally, Woodstock Corp bought a new stake in shares of FibroGen during the first quarter valued at about $271,000. Institutional investors and hedge funds own 49.82% of the company’s stock.
FibroGen Inc. (NASDAQ:FGEN) traded up 1.37% during trading on Friday, hitting $20.70. The stock had a trading volume of 468,215 shares. The firm’s market cap is $1.30 billion. The firm’s 50 day moving average is $19.38 and its 200 day moving average is $18.59. FibroGen Inc. has a 1-year low of $14.38 and a 1-year high of $31.90.
FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.36 by $0.01. FibroGen had a negative return on equity of 48.66% and a negative net margin of 61.90%. On average, analysts anticipate that FibroGen Inc. will post ($1.25) earnings per share for the current year.
Separately, Credit Suisse Group AG restated a “buy” rating and issued a $37.00 price objective on shares of FibroGen in a research report on Tuesday, August 9th.
In related news, CEO Thomas B. Neff sold 27,000 shares of FibroGen stock in a transaction on Wednesday, July 13th. The stock was sold at an average price of $17.50, for a total value of $472,500.00. Following the transaction, the chief executive officer now directly owns 3,412,664 shares in the company, valued at approximately $59,721,620. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas B. Neff sold 37,798 shares of FibroGen stock in a transaction on Friday, August 26th. The stock was sold at an average price of $17.80, for a total value of $672,804.40. Following the completion of the transaction, the chief executive officer now owns 3,403,639 shares in the company, valued at $60,584,774.20. The disclosure for this sale can be found here. 14.90% of the stock is owned by corporate insiders.
FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc. (NASDAQ:FGEN).
Receive News & Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.